Advertisement

Biotechnology Letters

, Volume 41, Issue 12, pp 1361–1371 | Cite as

Comparison of two commonly used methods for stimulating T cells

  • Juanjuan Jiao
  • Xincheng Zhao
  • Ruixia Hou
  • Ying Wang
  • Wenjuan Chang
  • Nannan Liang
  • Yanmin Liu
  • Jianxiao Xing
  • Yue Cao
  • Xiaofang Li
  • Kaiming ZhangEmail author
Original Research Paper
  • 149 Downloads

Abstract

Objective

Although several methods have been reported and used for in vitro T cell amplification, there are no consistent reports on the optimal stimulation conditions and the characterization of these stimulated T cells. The current study aimed to determine the optimal conditions for efficient T cell amplification by two commonly used methods involving CD3/CD28 antibody and phytohemagglutinin (PHA), respectively.

Results

Orthogonal design and CCK8 assay showed that 5 μg/mL CD3, 5 μg/mL CD28, and 100 ng/mL IL2 for the first method and 50 μg/mL PHA for the second method was optimal for T cell stimulation. Flow cytometry demonstrated that the percentage of CD8+ in the stimulated groups significantly increased, while the percentage of CD4+/CD8+ was significantly decreased compared with the unstimulated group. The percentage of CD4+ showed no significant difference among the three groups. Notably, there was no significant difference between the two stimulated groups. In addition, the percentage of apoptotic cells was significantly increased in the stimulated groups compared with the unstimulated group, but showed no remarkable difference between the PHA and CD3/CD28 stimulation groups. Glycolysis analysis showed that the glycolytic capacity and glycolytic reserve were both significantly increased in the PHA and CD3/CD28 groups compared with the unstimulated group, with no significant difference noted between the stimulated groups.

Conclusions

Although both stimulation methods showed similar efficacies, we suggest the PHA method might be better considering its easy application and cost-effective nature.

Keywords

Apoptosis CD3/CD28 CD4+/CD8+ Glycolysis PHA T lymphocytes 

Notes

Acknowledgements

This research was supported by National Nature Science foundation of China (Grant Nos. 81602768 and 81803146), and applied basic research foundation of Shanxi province (Grant No. 201801D221441).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Arad G, Levy R, Hillman D, Kaempfer R (2000) Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 6:414–421.  https://doi.org/10.1038/74672 CrossRefPubMedGoogle Scholar
  2. Arakaki R, Yamada A, Kudo Y, Hayashi Y, Ishimaru N (2014) Mechanism of activation-induced cell death of T cells and regulation of FasL expression. Crit Rev Immunol 34:301–314CrossRefGoogle Scholar
  3. Bashour KT et al (2014) CD28 and CD3 have complementary roles in T-cell traction forces. Proc Natl Acad Sci USA 111:2241–2246.  https://doi.org/10.1073/pnas.1315606111 CrossRefPubMedGoogle Scholar
  4. Bottcher M et al (2016) Mesenchymal stromal cells disrupt mTOR-signaling and aerobic glycolysis during T-cell activation. Stem Cells 34:516–521.  https://doi.org/10.1002/stem.2234 CrossRefPubMedGoogle Scholar
  5. Brunner T et al (1995) Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441–444.  https://doi.org/10.1038/373441a0 CrossRefPubMedGoogle Scholar
  6. Chang CH et al (2013) Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153:1239–1251.  https://doi.org/10.1016/j.cell.2013.05.016 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Fan XG, Huang Y, Tang FQ, Yi H (2000) Telomerase activity of peripheral blood lymphocytes in patients with chronic hepatitis B. Immunol Lett 73:7–11CrossRefGoogle Scholar
  8. Grossman Z, Min B, Meier-Schellersheim M, Paul WE (2004) Concomitant regulation of T-cell activation and homeostasis. Nat Rev Immunol 4:387–395.  https://doi.org/10.1038/nri1355 CrossRefPubMedGoogle Scholar
  9. Haining WN et al (2008) High-throughput gene expression profiling of memory differentiation in primary human T cells. BMC Immunol 9:44.  https://doi.org/10.1186/1471-2172-9-44 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Hombach A et al (2001) Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 167:6123–6131CrossRefGoogle Scholar
  11. Iezzi G, Karjalainen K, Lanzavecchia A (1998) The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8:89–95CrossRefGoogle Scholar
  12. Ilani T, Vasiliver-Shamis G, Vardhana S, Bretscher A, Dustin ML (2009) T cell antigen receptor signaling and immunological synapse stability require myosin IIA. Nat Immunol 10:531–539.  https://doi.org/10.1038/ni.1723 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Jorgensen JL, Reay PA, Ehrich EW, Davis MM (1992) Molecular components of T-cell recognition. Annu Rev Immunol 10:835–873.  https://doi.org/10.1146/annurev.iy.10.040192.004155 CrossRefPubMedGoogle Scholar
  14. Kanda H et al (2007) Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol 17:364–368.  https://doi.org/10.1007/s10165-007-0589-4 CrossRefPubMedGoogle Scholar
  15. Kang BH et al (2015) Analyses of the TCR repertoire of MHC class II-restricted innate CD4(+) T cells. Exp Mol Med 47:e154.  https://doi.org/10.1038/emm.2015.7 CrossRefPubMedPubMedCentralGoogle Scholar
  16. Kay JE (1991) Mechanisms of T lymphocyte activation. Immunol Lett 29:51–54CrossRefGoogle Scholar
  17. La Gruta NL, Liu H, Dilioglou S, Rhodes M, Wiest DL, Vignali DA (2004) Architectural changes in the TCR:CD3 complex induced by MHC:peptide ligation. J Immunol 172:3662–3669CrossRefGoogle Scholar
  18. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB (1999) Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5:1298–1302.  https://doi.org/10.1038/15256 CrossRefPubMedGoogle Scholar
  19. Li C et al (2016) Imbalance of Th17/Treg in different subtypes of autoimmune thyroid diseases. Cell Physiol Biochem 40:245–252.  https://doi.org/10.1159/000452541 CrossRefPubMedGoogle Scholar
  20. Lu P, Sharom FJ (1995) Gangliosides are potent immunosuppressors of IL-2-mediated T-cell proliferation in a low protein environment. Immunology 86:356–363PubMedPubMedCentralGoogle Scholar
  21. Maeda N, Sekigawa I, Iida N, Matsumoto M, Hashimoto H, Hirose S (1999) Relationship between CD4+/CD8+ T cell ratio and T cell activation in systemic lupus erythematosus. Scand J Rheumatol 28:166–170CrossRefGoogle Scholar
  22. Mirenda V et al (2007) Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 109:2968–2977.  https://doi.org/10.1182/blood-2006-10-050724 CrossRefPubMedGoogle Scholar
  23. Mishima T, Fukaya S, Toda S, Ando Y, Matsunaga T, Inobe M (2017) Rapid G0/1 transition and cell cycle progression in CD8(+) T cells compared to CD4(+) T cells following in vitro stimulation. Microbiol Immunol 61:168–175.  https://doi.org/10.1111/1348-0421.12479 CrossRefPubMedGoogle Scholar
  24. Noel PJ, Boise LH, Green JM, Thompson CB (1996) CD28 costimulation prevents cell death during primary T cell activation. J Immunol 157:636–642PubMedGoogle Scholar
  25. O'Flynn K, Russul-Saib M, Ando I, Wallace DL, Beverley PC, Boylston AW, Linch DC (1986) Different pathways of human T-cell activation revealed by PHA-P and PHA-M. Immunology 57:55–60PubMedPubMedCentralGoogle Scholar
  26. Onlamoon N et al (2006) Optimization of in vitro expansion of macaque CD4 T cells using anti-CD3 and co-stimulation for autotransfusion therapy. J Med Primatol 35:178–193.  https://doi.org/10.1111/j.1600-0684.2006.00182.x CrossRefPubMedGoogle Scholar
  27. Pandit H, Thakur G, Koippallil Gopalakrishnan AR, Dodagatta-Marri E, Patil A, Kishore U, Madan T (2016) Surfactant protein D induces immune quiescence and apoptosis of mitogen-activated peripheral blood mononuclear cells. Immunobiology 221:310–322.  https://doi.org/10.1016/j.imbio.2015.10.004 CrossRefPubMedGoogle Scholar
  28. Pollizzi KN, Powell JD (2014) Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol 14:435–446.  https://doi.org/10.1038/nri3701 CrossRefPubMedPubMedCentralGoogle Scholar
  29. Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500.  https://doi.org/10.1038/nri2785 CrossRefPubMedGoogle Scholar
  30. Skendros P, Sarantopoulos A, Tselios K, Boura P (2008) Chronic brucellosis patients retain low frequency of CD4+ T-lymphocytes expressing CD25 and CD28 after Escherichia coli LPS stimulation of PHA-cultured PBMCs. Clin Dev Immunol 2008:327346.  https://doi.org/10.1155/2008/327346 CrossRefPubMedGoogle Scholar
  31. Suhoski MM et al (2007) Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 15:981–988.  https://doi.org/10.1038/mt.sj.6300134 CrossRefPubMedPubMedCentralGoogle Scholar
  32. Sun H et al (2017) Tim3(+) Foxp3 (+) Treg Cells Are Potent inhibitors of effector T cells and are suppressed in rheumatoid arthritis. Inflammation 40:1342–1350.  https://doi.org/10.1007/s10753-017-0577-6 CrossRefPubMedGoogle Scholar
  33. Sundberg EJ, Deng L, Mariuzza RA (2007) TCR recognition of peptide/MHC class II complexes and superantigens. Semin Immunol 19:262–271.  https://doi.org/10.1016/j.smim.2007.04.006 CrossRefPubMedPubMedCentralGoogle Scholar
  34. Toth R, Szegezdi E, Molnar G, Lord JM, Fesus L, Szondy Z (1999) Regulation of cell surface expression of Fas (CD95) ligand and susceptibility to Fas (CD95)-mediated apoptosis in activation-induced T cell death involves calcineurin and protein kinase C, respectively. Eur J Immunol 29:383–393.  https://doi.org/10.1002/(SICI)1521-4141(199902)29:02%3c383:AID-IMMU383%3e3.0.CO;2-A CrossRefPubMedGoogle Scholar
  35. Trickett AE, Kwan YL, Cameron B, Dwyer JM (2002) Ex vivo expansion of functional T lymphocytes from HIV-infected individuals. J Immunol Methods 262:71–83.  https://doi.org/10.1016/s0022-1759(02)00018-2 CrossRefPubMedGoogle Scholar
  36. Turka LA, Ledbetter JA, Lee K, June CH, Thompson CB (1990) CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol 144:1646–1653PubMedGoogle Scholar
  37. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B (2000) Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol 1:47–53.  https://doi.org/10.1038/76907 CrossRefPubMedGoogle Scholar
  38. Wang L, Klimpel GR, Planas JM, Li H, Cloyd MW (1998) Apoptotic killing of CD4+ T lymphocytes in HIV-1-infected PHA-stimulated PBL cultures is mediated by CD8+ LAK cells. Virology 241:169–180.  https://doi.org/10.1006/viro.1997.8979 CrossRefPubMedGoogle Scholar
  39. Wang H, Daniel V, Sadeghi M, Opelz G (2013) Differences in the induction of induced human CD4(+) CD25(+) FoxP3(+) T-regulatory cells and CD3(+) CD8(+) CD28(-) T-suppressor cells subset phenotypes in vitro: comparison of phorbol 12-myristate 13-acetate/ionomycin and phytohemagglutinin stimulation. Transpl Proc 45:1822–1831.  https://doi.org/10.1016/j.transproceed.2012.10.061 CrossRefGoogle Scholar
  40. Waring P, Mullbacher A (1999) Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 77:312–317.  https://doi.org/10.1046/j.1440-1711.1999.00837.x CrossRefPubMedGoogle Scholar
  41. Wilkie S et al (2012) Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32:1059–1070.  https://doi.org/10.1007/s10875-012-9689-9 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Shanxi Key Laboratory of Stem Cells for Immunological Dermatosis, Institute of DermatologyTaiyuan Central Hospital of Shanxi Medical UniversityTaiyuanChina

Personalised recommendations